Paul Tudor Jones's NRIX Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 34,760 shares of Nurix Therapeutics, Inc. (NRIX) worth $659,397, representing 0.00% of the portfolio. First purchased in 2021-Q4, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in NRIX, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 37,943 shares. Largest reduction occurred in Q4 2024, reducing 22,259 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Nurix Therapeutics (NRIX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Nurix Therapeutics (NRIX) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -3,183 | Reduce 8.39% | 34,760 | $18.97 |
| Q3 2025 | +37,943 | New Buy | 37,943 | $9.24 |
| Q4 2024 | -22,259 | Sold Out | 0 | $0.00 |
| Q3 2024 | +211 | Add 0.96% | 22,259 | $22.47 |
| Q2 2024 | +22,048 | New Buy | 22,048 | $20.87 |
| Q1 2024 | -22,071 | Sold Out | 0 | $0.00 |
| Q4 2023 | +22,071 | New Buy | 22,071 | $10.32 |
| Q3 2023 | -12,991 | Sold Out | 0 | $0.00 |
| Q2 2023 | -9,115 | Reduce 41.23% | 12,991 | $9.99 |
| Q1 2023 | -56 | Reduce 0.25% | 22,106 | $0.01 |
| Q4 2022 | -35 | Reduce 0.16% | 22,162 | $0.01 |
| Q3 2022 | +1,848 | Add 9.08% | 22,197 | $13.02 |
| Q2 2022 | -2,200 | Reduce 9.76% | 20,349 | $12.68 |
| Q1 2022 | -2,300 | Reduce 9.26% | 22,549 | $14.01 |
| Q4 2021 | +24,849 | New Buy | 24,849 | $28.93 |
Paul Tudor Jones's Nurix Therapeutics Investment FAQs
Paul Tudor Jones first purchased Nurix Therapeutics, Inc. (NRIX) in Q4 2021, acquiring 24,849 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Nurix Therapeutics, Inc. (NRIX) for 15 quarters since Q4 2021.
Paul Tudor Jones's largest addition to Nurix Therapeutics, Inc. (NRIX) was in Q3 2025, adding 37,943 shares worth $350,593.
According to the latest 13F filing for Q4 2025, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 34,760 shares of Nurix Therapeutics, Inc. (NRIX), valued at approximately $659,397.
As of the Q4 2025 filing, Nurix Therapeutics, Inc. (NRIX) represents approximately 0.00% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Nurix Therapeutics, Inc. (NRIX) was 37,943 shares, as reported at the end of Q3 2025.